Clinical trials: Vertigo, Peripheral
Vestibular Vertigo
AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery
Treatment of vertigo after removal of a tumor of the balance and hearing nerve after neurosurgery, which damages or cuts the vestibular nerve (balance).
- Trial name
- TRAVERS (NCT03908567)
- Testing
- Intranasal Drug, Oral Tablet
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Auris Medical AG
Vertigo, Peripheral
Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin
Evaluation of the non inferiority of Meclin (meclizine) versus Dramin (Dimenhydrinate) to treat the symptoms of acute vertigo from peripheral origin after up to 4 weeks of treatment; Evaluation of impact on quality of life in…
- Trial name
- NCT02112578
- Testing
- Meclizine, Dimenhydrinate
- Where
- 7 sites in Brazil
- Volunteers
- 292 people
- Sponsor
- Apsen Farmaceutica S.A.
Vertigo
Effectiveness of Betaserc® (Betahistine Dihydrochloride) in Patients With Vestibular Vertigo in Routine Practice
The purposes of this international post-marketing observational program is to investigate effectiveness of betahistine dihydrochloride (Betaserc®) tablets and assess the course of vestibular vertigo after treatment…
- Trial name
- VIRTUOSO (NCT01759251)
- Where
- 24 sites in Russia, Ukraine
- Volunteers
- 309 people
- Sponsor
- Abbott
Lymphoma
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter…
- Trial name
- NCT03098589
- Testing
- Revlimid
- Where
- Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Meniere Disease, Vertigo
Safety of APSLXR in Patients Presenting Vertigo of Vestibular Origin or Meniere's Disease
The purpose of this study is to evaluate the safety of APSLXR in participants with Meniere's disease or other Verigo of vestibular origin. Pharmacokinetics will also be evaluated in a small group.
- Conditions
- Meniere Disease, Vertigo, Vertigo Vestibular
- Trial name
- NCT04674735
- Testing
- APSLXR
- Sponsor
- Apsen Farmaceutica S.A.
Multiple Myeloma
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form…
- Trial name
- NCT02921828
- Where
- 2 sites in United States, Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene